Prenetics Global Limited
PRENW
NASDAQ Global Market0.01
USD
- -
- -
CIK
0001876431
ISIN
KYG722451146
CUSIP
G72245114
Return %
Stock
S&P500
1Y
-68.64
16.05
3Y
-79.77
77.49
5Y
-99.03
72.82
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sheng Wu Yeung
- Full Time Employees
- 98
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- Unit 701-706, K11 Atelier King’s Road Hong Kong Hong Kong
- IPO Date
- Jul 16, 2021
- CIK
- 0001876431
- Website
- prenetics.com
- Similar Companies
- Business
- Prenetics Global Limited (PRENW) is a health sciences company focused on advancing consumer health through genomics-driven diagnostics, prevention services and wellness products in Hong Kong, the United States, Taiwan and internationally. Founded in 2014 and headquartered in Quarry Bay, Hong Kong, the company operates three main segments: Prevention, offering CircleDNA consumer genetic testing using next-generation sequencing for health, wellness and predisposition insights including nutrigenomics and pharmacogenomics; Diagnostics, providing precision oncology services through ACT Genomics such as ACTOnco comprehensive cancer tests for solid tumors, ACTHRD for homologous recombination deficiency and genomic profiling panels; and Consumer Health, selling premium supplements and wellness products under the IM8 brand alongside fulfillment and distribution of sports nutrition via the Europa Sports Partners brand. Prenetics recently acquired Europa Sports Partners and its subsidiary Hubmatrix in 2024 to expand into the US consumer health and wellness market projecting over $100 million in consumer segment revenue by fiscal 2025, launched IM8 as a flagship health brand in collaboration with figures like David Beckham, established the first consumer health company Bitcoin treasury with a strategic accumulation including 100 Bitcoin acquired in 2025 at an average $109,594 per coin, and saw executives announce open-market share purchases totaling approximately $1.45 million in November 2025. The company targets individual consumers, clinicians and athletes across biotechnology, health sciences and consumer health sectors with subsidiaries including ACT Genomics and IM8 Health.